Timeframe: 2010
Goal: Identify biomarkers
Principal Investigator: Michael Torbenson, MD, Department of Pathology, Johns Hopkins University (Currently at Mayo Clinic)
Early identification of tumors is essential for aggressive treatment. The majority of fibrolamellar carcinoma (FLC) patients have metastatic disease at the time of diagnosis. Therefore, identification of biomarkers for FLC is essential. Using a broad collection of FLC pathology specimens, the study planned to identify diagnostic biomarkers for FLC. In addition, they investigated whether these biomarkers are linked to any genetic mutations or microRNA expression profiles unique to FLC.